Trillium Renewable Chemicals | $13,000,000 | (May 7, 2026)
RadixArk | $100,000,000 | (May 7, 2026)
Astrada | $3,800,000 | (May 7, 2026)
Certified by Founder
Lodge
ImmunoScape
start up
Singapore
- Singapore
- 26/09/2022
- Unknown
- $14,000,000
ImmunoScape is a pre-clinical biotechnology company focused on the discovery and development of next-generation TCR cell therapies in the field of oncology. The company's proprietary Deep Immunomics technology platform enables highly sensitive, large-scale mining and immune profiling of T cells in cancer patient samples to identify novel, therapeutically relevant TCRs across multiple types of solid tumors. ImmunoScape has multiple discovery programs ongoing and will be progressing towards IND-enabling studies and entry into the clinic.
To learn more, visit us at immunoscape.com and follow us on Twitter @immunoscape.
- Industry Biotechnology Research
- Website https://immunoscape.com/
- LinkedIn https://www.linkedin.com/company/immunoscape/
Related People
Choon-Peng (Choon) NgFounder
Singapore -
Singapore
General Management. Cross functional and cross geography experience.
XCaliber Health | $6,500,000 | (May 7, 2026)
Cytospire Therapeutics Ltd | $82,984,705 | (May 7, 2026)
QuantWare | $178,775,560 | (May 7, 2026)
MOSH | $13,000,000 | (May 7, 2026)
InstaSwitch | $4,700,000 | (May 7, 2026)
Smartness | $55,270,590 | (May 7, 2026)
Scout Space | $18,000,000 | (May 7, 2026)
Altara | $7,000,000 | (May 7, 2026)
District | $14,700,000 | (May 7, 2026)